blank
blank

Dravet syndrome: Insights into seizure and speech progression from registry data

1:1
Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

This study utilises patient registry data to track the natural history of Dravet syndrome, focusing on how seizure frequency and speech abilities evolve over time. The findings provide a baseline for evaluating the efficacy of future therapeutic interventions.

Acces this publication
Epilepsy & Behaviour

Year of publication

2025

Source

Epilepsy & Behavior

Author

elporte M, Verbeeck J, Brambilla I, Zimmermann G, Molenberghs G, Nabbout R, et al.

You might also be interested in

ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.
European Biotech Act 062026

ERDERA Policy Brief: European Biotech Act

The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA News (1)

ERDERA Clinical Trial Call 2026: pre‑announcement and key dates

ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
ERDERA CTC 2026

ERDERA Clinical Trial Call 2026 – Pre-announcement

Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.

ERDERA's

search form